Information for Authors

 

About the Journal

Overview of Current Oncology
What we publish
Benefits of publishing with Current Oncology

Overview of Current Oncology

Current Oncology is a peer-reviewed, Canadian-based and internationally respected journal. Current Oncology represents a multidisciplinary medium encompassing health care workers in the field of cancer therapy in Canada to report upon and to review progress in the management of this disease.

What we publish

We encourage submissions from all fields of cancer medicine, including radiation oncology, surgical oncology, medical oncology, pediatric oncology, pathology, and cancer rehabilitation and survivorship. For a complete list of article areas that we publish, please visit http://www.current-oncology.com/index.php/oncology/about/submissions#JournalSections. Articles published in the journal typically contain information that is relevant directly to clinical oncology practice, and have clear potential for application to the current or future practice of cancer medicine.

Benefits of publishing with Current Oncology

  • Articles are freely and permanently accessible online immediately upon publication
  • Distributed in print gratis to the Canadian oncology community
  • Published articles are sent to and immediately available in PubMed Central (PMC)
  • Impact factor of 1.625, as published in the 2012 Journal Citation Reports, Science Edition
  • Is covered by the following major indexing services:
    • PubMed/PubMed Central
    • Embase
    • Science Citation Index Expanded (SciSearch)
    • Journal Citation Reports/Science Edition
    • EBSCOhost.com Research Databases
    • CrossRef
    • DOAJ (Directory of Open Access Journals)
    • Index Copernicus
    • Scopus
  • Published manuscripts will be invited to participate in the Cancer Knowledge Network, Current Oncology’s interactive dialogue Web site
  • Authors are granted specific rights for a large number of author uses

Return to Top

Peer Review Policy

All manuscripts are initially reviewed by the editorial staff, and if appropriate, will be assigned to a section editor. If the paper is judged to be suitable for possible publication, it will be sent to two or more external reviewers using our database of experts. All articles undergo this process with the following exceptions, which do not undergo our standard review process:

  • Letters to the Editor, Commentaries and Editorials are based on the decision of the Editor, who may ask experts on the merit of their contents.
  • Practices Guidelines/Consensus Statements - Special considerations may be made in this case as they are typically authored by experts in the field. The authors of the manuscript are asked to sign a form stating they have approved the manuscript and it is acceptable for publication. If they choose not to sign this, they must provide a list of five potential reviewers to review the manuscript, and the article will go through our standard peer review process. The Editors reserve the right to choose all reviewers and may not necessarily select reviewers from the list provided.
  • Meeting Reports – based on the decision of the Editor.
  • Special Articles – depending on the format and content, special articles may be solely based on the decision of the Editor, or undergo our standard review process.

Authors are permitted to submit the names and e-mail addresses of up to five individuals, who could, in their opinion, expertly review their manuscripts. The Editors, however, reserve the right to choose all reviewers.

Current Oncology employs a single-blind review process. The identities of the reviewers are kept confidential, but the identity of the author or authors is made known to the reviewers. The manuscript under review is not revealed to anyone other than the reviewers and editorial staff. Reviewers are required to maintain confidentiality about the manuscripts they review. Authors should expect to receive an initial decision on their manuscript within 2–6 weeks of submission. If revision of the manuscript is required, the authors must submit within three weeks of the request.

Return to Top

Types of Submissions

Outlined below are the types of submissions accepted to Current Oncology. For further details about the requirements of each article type, view the “Instructions for Submissions” section.

Please note: Below are ONLY guidelines that authors should follow. The suggested word, table and figure counts for an article are provided to keep manuscripts at a length that will maintain the interest of our reviewers and readership. Article Processing Fee (APF) and Extra Page Charges (EPC) will apply to all manuscripts including; review articles, case reports, original articles, perspective pieces, short communication, guidelines and consensus statements. The APF is $750.00 CDN, which includes up to four black & white published pages. EPC of $100.00 CDN per b&w page will apply for each additional published page over four pages. Letters to the editor, editorials, cancer narratives, commentaries and invited guest editorials are exempt from paying this fee.

To help determine the approximate author fees for an article, please send an email to current_oncology@multi-med.com for an estimated published page count. Please provide your full article in word document format, along with any figures and tables. If the manuscript has already been submitted, please provide the manuscript title or ID. Please note an accurate page count of your article and the associated fees can only be determined once the article is in final PDF galley format.

Article Type

Description

Suggested Word Count Limit

Other

Peer Reviewed
(Yes or No)

Original Articles

Investigations and original research that represent new and significant contributions and advances to the field of oncology

3000–4000

4–6 Tables/figures and a limit of 50 references where appropriate

Yes

Review Articles

Reviews of major areas or sub-areas in the field of oncology. Describe new developments, summarize progress, or analyze published evidence

3000–4000

4–6 Tables/figures and a suggested 75-reference limit.

Yes

Editorials

Comments from recognized experts on a specific topic, and related to an article published in the same issue. Editorials are generally solicited by the Editorial team

1500

1–2 Tables/figures and 4–8 references

No

Commentaries

Opinions/views of recognized experts on a specific topic. Commentaries are unrelated to a specific article and provide an opinion or view on an oncology related topic. Commentaries can address various controversial and timely issues in oncology

2000

1–2 tables/figures and 4–8 references

No

Practice Guidelines

Clinical guidelines and consensus statements

4000

4–6 Tables/figures and a suggested 50-reference limit

Consensus Guidelines are normally authored by experts. The authors on the manuscript are asked to sign a form stating they have approved the manuscript and it is acceptable for publication. If they choose not to sign this, they must provide a list of five potential reviewers to review the manuscript.

Letters to the Editor

Comments on papers previously published in Current Oncology or on any other matters of interest to Oncology

500–750

Should not have tables or figures, and no more than 5 references

No

Perspectives in Oncology

Discuss significant topics and controversies relevant to oncology. These articles are typically from a more personal or opinion-based standpoint than a Review Article

2500

4–6 Tables/figures and a suggested 50-reference limit

Yes

Short Communications

Brief reports of preliminary or limited results of original research, observations, or case series on the causes, mechanisms, diagnosis, course, treatment, and prevention of cancer

1500

1–2 Tables/figures and 15–20 references

Yes

Case Reports

Reports on oncology-specific cases

1500

3–4 Tables/figures and 25 references

Yes

Meeting ReportsReports should focus on the key developments presented and discussed at the Oncology related meeting

1500-3500

3–4 Tables/figures and 25 references

No

Cancer Narratives: Words Beyond Disease

Articles should focus on issues or themes of general relevance from a personal or unique perspective. Creative writing with a cancer-related theme, as well as descriptions of struggles, conflicts, joys and emotions encountered in clinical practice are encouraged.

1500

2 Tables/figures (if required), and no more than 8 references (if required)

Yes

Return to Top

Instructions for Submissions

Original articles
Review articles
Editorials
Commentaries
Practice guidelines
Letters to the Editor
Perspectives in oncology
Short communications
Case reports
Meeting reports
Cancer Narratives: Words Beyond Disease

Please note: Below are ONLY guidelines that authors should follow. The suggested word, table and figure counts for an article are provided to keep manuscripts at a length that will maintain the interest of our reviewers and readership. Article Processing Fee (APF) and Extra Page Charges (EPC) will apply to all manuscripts including; review articles, case reports, original articles, perspective pieces, short communication, guidelines and consensus statements. The APF is $750.00 CDN, which includes up to four black & white published pages. EPC of $100.00 CDN per b&w page will apply for each additional published page over four pages. Letters to the editor, editorials, cancer narratives, commentaries and invited guest editorials are exempt from paying this fee.

To help determine the approximate author fees for an article, please send an email to current_oncology@multi-med.com for an estimated published page count. Please provide your full article in word document format, along with any figures and tables. If the manuscript has already been submitted, please provide the manuscript title or ID. Please note an accurate page count of your article and the associated fees can only be determined once the article is in final PDF galley format.

Original articles

Original articles describe investigations and original research that represent new and significant contributions and advances in the oncology field. Submissions from all fields are welcome (see Journal Sections listing for further details).

Instructions:

  • Total word count (excluding abstract, references and text for tables and figures) should not exceed 4000 words
  • Abstract should be no longer than 250 words
  • Total number of tables and figures and tables should not exceed 6
  • Suggested limit of 50 references and should be limited to recent works

Review articles

Review articles examine major areas or sub-areas in the field of oncology. The purpose is to describe new developments, summarize progress or analyze published evidence.

Instructions:

  • Total word count (excluding abstract, references and text for tables and figures) should not exceed 4000 words
  • Abstract should be no longer than 250 words
  • Total number of tables and figures and tables should not exceed six
  • Suggested limit of 75 references

Editorials

Editorials are most often solicited by the Editors, and are related to an article published in the same issue. They express the opinions and views of recognized experts on a specific topic.

Instructions:

  • Total word count should not exceed 1500 words (excluding references and text for tables and figures)
  • No abstract
  • Total number of tables and figures and tables should not exceed two
  • Limit of 8 references
  • Limited or no subheadings within the body of the manuscript

Commentaries

Commentaries are most often solicited by the Editors, and are not related to a specific article. They express the opinions and views of recognized experts on a specific topic. The commentary format may be used for ongoing dialogues, discussions of controversial issues, or subjective articles of interest in any field of oncology.

Instructions:

  • Total word count should not exceed 2000 words (excluding references and text for tables and figures)
  • No abstract
  • Total number of tables and figures and tables should not exceed 2
  • Limit of 8 references
  • Limited or no subheadings within the body of the manuscript

Practice guidelines

Clinical practice guidelines and published statements, intended to guide clinical and patient care (for example, Guidelines, Recommendations, Consensus Statements, and Position Papers).

Instructions:

  • Total word count (excluding abstract, references and text for tables and figures) should not exceed 4000 words
  • Abstract should be no longer than 250 words
  • Total number of tables and figures and tables should not exceed 6
  • Suggested limit of 50 references
  • The “Author declaration of acceptance/suggested reviewer form” form must be completed and submitted with the manuscript.

Letters to the Editor

Letters to the Editor should comment on work previously published in Current Oncology. Letters must be submitted within one month of the online publication date of the article discussed in order to be considered. Their publication is based only on the decision of the Editor, who occasionally asks experts on the merit of the contents. The Editors may invite a reply to the letter by the original author. The Editor may consider publication of a letter that comments on other matters of interest to Oncology. This section is not considered to be an appropriate venue for publishing new data without peer review. Studies with scientific merit should be considered for submission as an Original Article or Short Communication.

Instructions:

  • Total word count should not exceed 750
  • No tables or figures are to be included
  • Limit of 5 references

Perspectives in oncology

These articles discuss significant topics and controversies relevant to oncology. These articles are typically from a more personal or opinion-based standpoint than a Review Article. Perspectives should state the topic and background information concisely, discuss opposing viewpoints, and make recommendations for further investigations or actions. Interested authors should correspond with the Editor prior to submission to discuss the suitability of the proposed subject matter.

Instructions:

  • Total word count (excluding abstract, references and text for tables and figures) should not exceed 2500 words
  • Abstract should be no longer than 250 words
  • Total number of tables and figures and tables should not exceed 4
  • Suggested limit of 50 references

Short communications

These articles are brief reports of preliminary or limited results of original research, observations, or case series on the causes, mechanisms, diagnosis, course, treatment, and prevention of cancer.

Instructions:

  • Total word count (excluding abstract, references and text for tables and figures) should not exceed 1500 words
  • Abstract should be no longer than 250 words and must not contain headings
  • Total number of tables and figures and tables should not exceed 3
  • Suggested limit of 20 references

Case reports

Case report articles report on oncology-specific cases. Cases will typically be judged on clinical interest and educational value to the oncology field and NOT novelty or rarity.

Instructions:

  • Total word count should not exceed 1500 (excluding abstract, references and text for tables and figures)
  • Include an unstructured abstract of no more than 250 words that summarizes the report
  • Include a concise overview describing the case and brief literature review
  • Limit of 4 tables or figures
  • Limit of 25 references

Meeting reports

Reports should focus on key developments presented and discussed at an Oncology related meeting.

Instructions:

  • Total word count should not exceed 3500 (excluding abstract, references and text for tables and figures).
  • Abstract should be no longer than 250 words
  • Total number of tables and figures and tables should not exceed four
  • Suggested limit of 25 references

Cancer Narratives: Words Beyond Disease

Submissions to 'Cancer Narratives' are welcomed from all members of the cancer care community and should focus on issues or themes of general relevance from a personal or unique perspective. Creative writing with a cancer-related theme, as well as descriptions of struggles, conflicts, joys and emotions encountered in clinical practice, potentially resonating with the broader cancer care community, including patients and their loved ones, are strongly encouraged.

Submissions from learners at all levels, as well as anyone involved with cancer care including nurses, supportive care providers and pharmacists, for example, are welcomed. Personal perspectives from patients and their loved ones are also encouraged.

Instructions:

  • Total word count should not exceed 1500 words
  • No abstract required
  • If required, total number of tables and figures should not exceed two
  • Limit of 8 references (if required)

Return to Top

Journal Sections

For all Original Articles authors will be asked to select one of the applicable sub-sections upon article submission:

  • Biomarkers in Oncology
  • Biomedical Ethics
  • Bone and Soft Tissue Oncology
  • Cancer Genetics
  • Cancer Rehabilitation and Survivorship
  • Clinical Trials
  • Geriatric Oncology
  • Immuno-Oncology
  • Integrative Oncology
  • Knowledge Translation*
  • Medical Economics
  • Medical Legal
  • Medical Oncology
  • Nursing
  • Nutrition
  • Oncofertility
  • Oncologic Pathology
  • Oncology Education
  • Palliative Oncology
  • Pediatric Oncology
  • Psychosocial Oncology
  • Radiation Oncology
  • Surgical Oncology
  • Translational Research
  • Urologic Oncology

* Articles submitted to the Knowledge Translation section must follow the format as outlined in the Manuscript Preparation Guidelines

Other journal sections include:

  • Case Reports
  • Cancer Narratives: Words Beyond Disease
  • Commentaries (Includes Updates and Developments in Oncology - a standing series of commentaries invited by the editors of the section Drs. Phil Gold and Richard Ablin)
  • Guest Editorials
  • Letters to the Editor
  • Meeting Abstracts
  • Meeting Reports
  • Perspectives in Oncology
  • Practice Guidelines
  • Review Articles
  • Short Communications
  • Special Articles

Return to Top

Authors' Professional and Ethical Responsibilities

Authorship
Sources of support
Conflict of interest
Previous or duplicate publication
Informed consent
Human and animal rights

Authorship

Only those persons who contributed directly to the intellectual content of the paper should be listed as authors. Authors should meet all of the following criteria:

  1. Conceived and planned the work that led to the paper.
  2. Wrote the paper, or reviewed successive versions and took part in the revision process.
  3. Approved the final version.

Holding positions of administrative leadership, contributing patients, and collecting and assembling data, are not, by themselves, criteria for authorship. Other persons who have made substantial, direct contributions to the work but cannot be considered authors should be listed in the Acknowledgments section. Examples of those who might be acknowledged include a person who provided purely technical help, writing assistance, or a department chair who provided only general support.

Sources of support

Sources of outside support for research, including funding, grants, equipment, and drugs, must be named in the title page and in the Acknowledgment statement. The role of the funding organization, if any, in the collection of data, its analysis and interpretation, and in the right to approve or disapprove publication of the finished manuscript must be described in the Methods section of the text.
Any involvement of medical writers/researchers, particularly those employed or supported by the pharmaceutical industry, in the writing of an article must be clearly defined and disclosed and also included in the Acknowledgment statement.

Conflict of interest

Public trust in the peer review process and the credibility of published articles depends in part on how well conflict of interest is handled during writing, peer review, and editorial decision-making. Conflict of interest exists when an author (or the author's institution), reviewer, or editor has financial or personal relationships that inappropriately influence (bias) his or her actions. (Such relationships are also known as dual commitments, competing interests, or competing loyalties.) These relationships vary from those with negligible potential to those with great potential to influence judgment, and not all relationships represent true conflicts of interest. The potential for conflict of interest can exist whether or not an individual believes that the relationship affects his or her scientific judgment. Financial relationships (such as employment, consultancies, stock ownership, honoraria, paid expert testimony) are the most easily identifiable conflicts of interest and the most likely to undermine the credibility of the journal, the authors, and of science itself. However, conflicts can occur for other reasons, such as personal relationships, academic competition, and intellectual passion. All authors must disclose on the article’s title page if any conflict of Interest exists. The Conflict of Interest Disclosure will be published at the end of text, before the references section. If no conflicts exist, please state “The authors have no conflicts of interest to declare.”

Previous or duplicate publication

On the title page, give full details on any possible previous or duplicate publication of any content of the paper. Previous publication of a small fraction of the content of a paper does not necessarily preclude its being published, but the Editors need information about previous publication when deciding how to use space in the Journal efficiently; they regard failure of full disclosure by authors of possible prior publication as a breach of scientific ethics. Please send a copy of any document that might be considered a previous publication.

Informed consent

Patients have a right to privacy that should not be infringed without informed consent. Identifying information, including patients' names, initials, or hospital numbers, should not be published in written descriptions, photographs, and pedigrees unless the information is essential for scientific purposes and the patient (or parent or guardian) gives written informed consent for publication. Informed consent for this purpose requires that a patient who is identifiable be shown the manuscript to be published. Identifying details should be omitted if they are not essential. Nonessential identifying details should be omitted. Informed consent should be obtained if there is any doubt that anonymity can be maintained. For example, masking the eye region in photographs of patients is inadequate protection of anonymity. If identifying characteristics are altered to protect anonymity, such as in genetic pedigrees, authors should provide assurance that the alterations do not distort the scientific purpose. When appropriate, authors must state in the Methods section the procedure used to ensure adherence to ethical guidelines on informed consent and should affirm that such consent was obtained.

Human and animal rights

When reporting experiments on human subjects, authors should indicate whether the procedures followed accord with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2008. If doubt exists whether the research was conducted in accordance with the Helsinki Declaration, the authors must explain the rationale for their approach and demonstrate that the institutional review body explicitly approved the doubtful aspects of the study. When reporting experiments on animals, authors should indicate whether the institutional and national guide for the care and use of laboratory animals was followed.

Return to Top

Manuscript Preparation Guidelines

In addition to the preparation guidelines provided, authors may refer to the International Committee of Medical Journal Editors (ICMJE)'s "Preparing a Manuscript for Submission to a Biomedical Journal" for additional advice on appropriate manuscript preparation.

Structure and Presentation
Title Page
Abstract and key words
Text
References
Figures
Tables

Structure and Presentation

Write the body of the manuscript as concisely as possible, adhering to the word limits specified for the given manuscript category. Use at least line-and-a-half spacing throughout, including in the references and figure legends.

For section and subsection headings, please use the heading styles built into your word processing template. Headings are numbered, to a maximum of three levels:

3. LEVEL ONE HEADING
3.1 Level 2 Heading
3.1.1 Level 3 Heading

If further divisions of the text are required, use inline headings:

In-line Heading Level One: Paragraph text ....
In-line Heading Level Two: Paragraph text ....

Focus on the content rather than the look of a submission. Simpler is always better. Use a common typeface such as Verdana, Arial, Helvetica, or Times in a readable size (11 or 12 points is usually adequate). In running text, formatting other than the usual uses of italic, superscript, and subscript is discouraged. During the copyediting process all extraneous formatting will, in any case, be stripped from the file to ensure smooth intake into the layout program used by the page compositor.

All papers must contain the following items, when applicable:

The linked sections provide further instructions for preparation of these items.

Title Page

The first page of the manuscript should set out

  1. the title of the article (80 characters maximum, using sentence case).
  2. the names of the authors (written as initials and surname), with academic degree(s) attained. Omit “candidate,” “fellow,” and “diplomate” designations, but include “registered” designations. Correct: J.A. Smith MD, P. Jones MSc, T. Ryan RD. Incorrect: J.A. Smith MD FRCP, P. Jones PhD(Cand).
  3. the affiliation or affiliations for each author. For each affiliation, include the name of the department (if any), the institution, the city, and the province (if Canada, using the official postal abbreviation) or the state (if applicable) and country where the work was done. Link the authors to their designations using these characters in the order shown: * (asterisk, never superscripted) † (superscript dagger) ‡ (superscript double dagger) § (superscript section mark) || (superscript double bar) # (superscript octothorpe). For the seventh and subsequent affiliations (if needed), use the same characters in the same sequence, but paired—that is, ** †† ‡‡ and so on.
  4. a shortened version of the title for use as a running header (no more than 60 characters, upper case).
  5. the usual full name of the corresponding author, with postal address, e-mail address, and fax and telephone numbers.
  6. acknowledgments of grant support and of individuals who were of direct help in the preparation of the study or the manuscript.
  7. source or sources of support in the form of grants, equipment, drugs, or all of these.
  8. full details on any possible previous or duplicate publication of any content of the paper (if applicable).
  9. a word count for the text only (excluding abstract, acknowledgments, figure legends, and references).
  10. the number of figures and tables.

Abstract and key words

Include a structured abstract of no more than 250 words for original and review articles. Use these subheadings:

  • Background
  • Methods
  • Results
  • Conclusions (or Summary)

For other major manuscripts, include an unstructured abstract of no more than 250 words that summarizes the objective, main points, and conclusions of the article. Abstracts are not required for editorials, commentaries, and letters to the editor.

After the abstract, list up to eight key words or phrases for indexing. A list of key words is required for all submissions. Present the key words in one paragraph, separated by commas, with no terminal punctuation.

Text

Organization
Spelling
Abbreviations
Units of Measurement
Special Characters
Proprietary and Generic Names
Use of English Language

Organization

Organize the text using the applicable structure from the list set out here.

For review and original articles:

  • Introduction (or Background)
  • Methods
  • Results
  • Discussion
  • Conclusions (or Summary)
  • Acknowledgments
  • Conflict of Interest Disclosures
  • References
  • Appendices (optional)
  • Figure Legends
  • Tables

For Knowledge Translation articles:

  • Background
    What is the specific knowledge-to-practice gap that the project was designed to address; what were the specific objectives of the project; what knowledge translation theory, model, or framework was used to inform the project?
  • Implementation
    What was the specific knowledge translation strategy that was developed and implemented to meet the objectives; how was the project evaluated (describe the specific measures); what were the results of the evaluation; was an economic evaluation undertaken?
  • Discussion
    What conclusions were drawn from the evaluation (if not successful, why not); was a decision taken to continue or to abandon the activity; what might have been done differently; are the results generalizable to other cancer control domains or other jurisdictions in Canada; is the project sustainable?
  • Acknowledgments
  • Conflict of Interest Disclosures
  • References
  • Appendices (optional)
  • Figure Legends
  • Tables

For Short Communications:

For Case Reports:

For examples of Practice Guidelines, Cancer Narratives, and Meeting Reports, please view previously published material at www.current-oncology.com.

Spelling

Use Canadian spelling. In this context, “Canadian” spelling means using “–our” and “–re” word endings (“rigour,” “centre”) and doubled consonants in most verb forms (“signalling,” “modelling”). However, “–ize” and “–yze” are the preferred verb endings (“characterize” not “characterise” and “analyze” not “analyse”), and diphthongs are not used (for example, “hemoglobin” not “haemoglobin” and “diarrhea” not “diarrhoea”). Use the serial comma (sometimes called the “Oxford” comma).

Abbreviations

Multi-word phrases used frequently (four times or more) in the text may be abbreviated if necessary. Introduce the abbreviation in parentheses after the first occurrence of the phrase, and then use the abbreviation at the second and subsequent appearances [for example, “chronic lymphocytic leukemia (CLL)”, “progression-free survival (PFS)”]. Note that, with respect to introducing and using abbreviations, the abstract, main body of the article, and each figure and table are considered entirely separate entities, and the abbreviation rule applies to each entity separately, except that in the abstract and figures, abbreviations can be introduced even if the abbreviated phrase is repeated only once or twice.

Note that sentences may never begin with an abbreviation. Rewrite to avoid or spell the phrase in full.

Abbreviations for units of measurement and standard scientific symbols (for example, 3 mL, Na, DNA) may be used without explanation, as may the standard abbreviations for the long names of chemical substances (for example, EDTA). Chemotherapeutic regimens may be shown as abbreviations on first (or even only) reference, but list the component drugs in parentheses [for example, FOLFIRI (irinotecan–5-fluorouracil–leucoverin)]. Abbreviate names of tests and procedures that are better known by their abbreviations than by the full name (VDRL test, SMA-12).

Abbreviations used in figures must be defined in the figure legend. In tables, strive for a balance between readability and space-saving through abbreviation. For examples, please view previously published material at www.current-oncology.com.

Units of Measurement

Use the SI system, and its standard symbols, throughout the manuscript. When units other than SI units are widely used, they can be indicated in parentheses after the SI unit. When a unit of measurement is mentioned outside the context of a specific quantity, spell out the full name of the unit (for example, “measured in milliliters”, but “aliquots of 10 mL were centrifuged”). In tables, specify the units for a column or row in the column or row stub rather than in every entry in the column or row.

Special Characters

Certain symbols that are frequently used in biomedical publications (Greek and mathematical symbols primarily) do not usually import correctly from word processing files into page layout programs. Authors can feel free to use these symbols, but during the copyediting process, they will be changed into codes that the page compositor can locate in a search-and-replace operation to drop the correct symbols into the laid-out pages. On no account should the codes added by the copyeditor be altered by the author during the author’s copyedit review step. (Some examples of these codes are “xxa” for alpha, “xx>” for “greater than or equals,” and “xxby” for the multiplication symbol.)

Proprietary and Generic Names

Use generic names for all drugs. Include the proprietary name, with the owner’s name and headquarters location in parentheses [that is, city, province|state, country—for example, “trastuzumab (Herceptin: Genentech, San Francisco, CA, U.S.A.)”], only if it is more commonly known than the generic name; to differentiate among drug forms; or if a specific trade preparation was used in a study or was involved in an adverse effect. Instruments may be referred to by their proprietary name; the name and headquarters location of the manufacturer must be given in parentheses in the text.

Use of English Language

All papers are published in English, and authors who are not fluent in English are advised to seek editorial help before submitting their papers. This will help to ensure that the academic content of the paper is fully understood by the journal editors and reviewers.

References

With some minor modifications, Current Oncology follows the stylistic standard outlined in the Uniform Requirements for Manuscripts Submitted to Biomedical Journals (http://www.nlm.nih.gov/bsd/uniform_requirements.html, http://www.ncbi.nlm.nih.gov/books/NBK7256/). The Uniform Requirements style is based to a large extent on the standard used by the U.S. National Library of Medicine (NLM) for its databases. Journals titles should be abbreviated according to the style used in the list of Journals Indexed for MEDLINE, posted by the NLM on the Library's Web site; http://www.nlm.nih.gov/tsd/serials/lji.html.

The manuscript’s reference list must be numbered (using Arabic numerals) consecutively in the order in which the references are first cited in the text. Citations appearing in tables and figures must fit into the numbering sequence from the point at which the table or figure is first mentioned in the text.

In text, tables, and legends, reference citations are to be presented as superscripts. Do not use ibid. or op cit.

Reference Recap:

  1. Use the reference style of the Uniform Requirements as based largely on the standard adapted by the National Library of Medicine for its databases.
  2. Number references in the order in which they are first cited in the text, with citations in figures and tables being incorporated into the order at the point where the figure or table is first mentioned.
  3. All citations are expected to appear as superscript numerals.
  4. Provide complete data for each reference.
  5. Cite symposium papers only from published proceedings.
  6. When citing an article or book accepted for publication but not yet published, include the title of the journal (or name of the publisher) and the year of expected publication.
  7. Include citations of unpublished material in the text, not in the references [for example, papers presented orally at a meeting; unpublished work (personal communications, papers in preparation)] and submit a letter of permission from the cited persons to cite such communications.
  8. Include an “available from” note for documents that may not be readily accessible.

Minimum Acceptable Data for Basic References

Print Journal – Full article
Online Journal – Full article
Print Journal – Abstract
Proceedings Book – Abstract
Print Book or Pamphlet
Print Book Chapter
Online Book, Pamphlet, or Book Chapter
Web Site
Newspaper or Magazine Article
Special Formats
Unpublished Material

Print Journal – Full article

Author or authors (for up to 6, include all names; for 7 or more, include 3 names and add “et al.”; for authors acting for group, add “on behalf of the <Group Name>” after author names; for authorship credited to a group, use the group name). Title of article in sentence case. Journal Name Year;Vol:pp–pp.

Examples:
Geomini P, Kruitwagen R, Bremer GL, Cnossen J, Mol BW. The accuracy of risk scores in predicting ovarian malignancy: a systematic review. Obstet Gynecol 2009;113:384–94.

Maggioni A, Benedetti Panici P, Dell’Anna T, et al. Randomised study of systematic lymphadenectomy in patients with epithelial ovarian cancer macroscopically confined to the pelvis. Br J Cancer 2006;95:699–704.

Wirth MP, See WA, McLeod DG, Iversen P, Morris T, Carroll K on behalf of the Casodex Early Prostate Cancer Trialists’ Group. Bicalutamide 150 mg in addition to standard care in patients with localized or locally advanced prostate cancer: results from the second analysis of the early prostate cancer program at median follow up of 5.4 years. J Urol 2004;172:1865–70.

Online Journal – Full article

To the standard information for a print article, add “[Available at: <http://FullURL>; cited Month DD, YYYY]” to the end of the reference.

Example:
Al-Saleh K, Quinton C, Ellis PM. Role of pemetrexed in advanced non-small-cell lung cancer: meta-analysis of randomized controlled trials, with histology subgroup analysis. Curr Oncol 2012;19:e9–15. [Available at: http://www.current-oncology.com/index.php/oncology/article/view/891/817; cited June 24, 2012]

Print Journal – Abstract

Abstract author or authors (for up to 6, include all names; for 7 or more, include 3 names and add “et al.”; for authors acting for group, add “on behalf of the <Group Name>” after author names; for authorship credited to a group, use the group name). Title of abstract in sentence case [abstract <number>]. Journal Name Year;Vol:pp–pp.

Example:
Lee JS, Park K, Kim SW, et al. A randomized phase III study of gefitinib versus standard chemotherapy (gemcitabine plus cisplatin) as a first-line treatment for never-smokers with advanced or metastatic adenocarcinoma of the lung [abstract PRS.4]. J Thorac Oncol 2009;4(suppl 1):S283.

For organizations that maintain online archives of published meeting abstracts (for example the American Society of Clinical Oncology meeting abstract archive, and the San Francisco Breast Cancer Symposium abstract archive) omit the page number. Instead, add the direct URL to the abstract in the organization’s archive (“[Available online at: <http://FullURL>; cited Month DD, YYYY]”) to the end of the reference.

Examples:
Kwak EL, Camidge DR, Clark J, et al. Clinical activity observed in a phase I dose escalation trial of an oral c-Met and Alk inhibitor, PF-02341066 [abstract 3509]. J Clin Oncol 2009;27:. [Available online at: http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=65&abstractID=30947; cited May 23, 2012]

Di Leo A, Isola J, Piette F, et al. A meta-analysis of phase III trials evaluating the predictive value of HER2 and topoisomerase II alpha in early breast cancer patients treated with CMF or anthracycline-based adjuvant therapy [abstract 705]. Breast Cancer Res Treat 2008;107:. [Available online at: http://www.abstracts2view.com/sabcs/view.php?nu=SABCS08L_538; cited June 21, 2011]

Proceedings Book – Abstract

Abstract author or authors (for up to 6, include all names; for 7 or more, include 3 names and add “et al.”; for authors acting for group, add “on behalf of the <Group Name>” after author names; for authorship credited to a group, use the group name). Title of abstract in sentence case [abstract <number>]. In: Editors for proceedings book (up to 6, include all names; 7 or more, include 3 names and add “et al.”), eds. Title of Proceedings Book in Title Caps. Proceedings of <Meeting Name>; Conference City, State|Province|Country; Conference Month DD–DD, Year. Publisher City, State|Province|Country: Publisher; Publication Year: pp–pp.

Example:
Bengtsson S, Solheim BG. Enforcement of data protection, privacy and security in medical informatics. In: Lun KC, Degoulet P, Piemme TE, Rienhoff O, eds. MEDINFO 92. Proceedings of the 7th World Congress on Medical Informatics; Geneva, Switzerland; September 6–10, 1992. Amsterdam: North–Holland; 1992: 1561–5.

Print Book or Pamphlet

Author or authors (for up to 6, include all names; for 7 or more, include 3 names and add “et al.”; for authors acting for group, add “on behalf of the <Group Name>” after author names; for authorship credited to a group, use the group name). Title of Book in Title Caps. Edition number (if edition 2 or later). City, State|Province|Country: Publisher; Year.

Examples:
Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, eds. AJCC Cancer Staging Manual. 7th ed. Chicago, IL: Springer; 2009.

Sneiderman B, Irving JC, Osborne PH. Canadian Medical Law: An Introduction for Physicians, Nurses and Other Health Care Professionals. 3rd ed. Toronto, ON: Thompson–Carswell; 2003.

Canadian Cancer Society’s Steering Committee. Canadian Cancer Statistics 2010. Toronto, ON: Canadian Cancer Society; 2010.

Australia, Department of Health and Ageing, Australian Cancer Network, National Breast Cancer Centre (NBCC). Clinical Practice Guidelines for the Management of Women with Epithelial Ovarian Cancer. Camperdown, Australia: NBCC; 2004.

AstraZeneca Canada. IRESSA (Gefitinib Tablets) [product monograph]. Mississauga, ON: AstraZeneca Canada; 2009.

Print Book Chapter

Chapter author or authors [up to 6, include all names; 7 or more, include 3 names and add “et al.”). Title of chapter in sentence case. In: Editors of book (up to 6, include all names; 7 or more, include 3 names and add “et al.”), eds. Title of Book in Title Caps. Edition number (if edition 2 or later). City, State|Province|Country: Publisher; Year: pp–pp.

Example:
Ellis MJ, Hayes DF, Lippman ME. Treatment of metastatic breast cancer. In: Harris JR, Lippman ME, Morrow M, Osborne K, eds. Diseases of the Breast. 2nd ed. Philadelphia, PA: Lippincott Williams and Wilkins; 2000: 749–97.

Online Book, Pamphlet, or Book Chapter

To one of the standard print formats, add “[Available online at: <http://FullURL>; cited Month DD, YYYY]” to the end of the reference.

Example:
United States, Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Cancer Therapy Evaluation Program (CTEP). Common Terminology Criteria for Adverse Events. Ver. 3.0. Bethesda, MD: CTEP; 2006. [Available online at: http://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcaev3.pdf; cited May 27, 2012]

Web Site

Note that bare URLs or the home page of an organization are unacceptable references. Full publication details and a direct URL to the information being cited is required.

Author (or, if no author is available, the name of the organization responsible for the site). Page Title in Title Case [Web page|Web resource|Web article|blog post]. City, State|Province|Country: Publisher; Year (if item is undated, use “n.d.”). [Available at: <http://FullURL>; cited Month DD, YYYY]

Examples:
Government of Newfoundland and Labrador. Commission of Inquiry on Hormone Receptor Testing [Web page]. St. Johns’s, NL: Government of Newfoundland and Labrador; 2009. [Available at: http://www.cihrt.nl.ca; cited January 10, 2012]

BC Cancer Agency (BCCA). BC Cancer Agency > Health Professionals Info > Cancer Management Guidelines > Lymphoma (Including Chronic Leukemia and Myeloma) [Web resource]. Vancouver, BC: BCCA; n.d. [Available at: http://www.bccancer.bc.ca/HPI/CancerManagementGuidelines/Lymphoma/default.htm; cited December 10, 2011]

Flynn J. Pressured to Die: Euthanasia Push Continues [Web page]. Rome, Italy: Catholic.net; 2011. [Available at: http://catholic.net/index.php?option=dedestaca&id=6480&grupo=Life%20%20Family&canal=Life%20and%20Bioethics; cited November 26, 2011]

Wikipedia. Legality of Euthanasia: Netherlands [Web article]. San Francisco, CA: Wikimedia Foundation; n.d. [Available at: http://en.wikipedia.org/wiki/Legality_of_euthanasia#Netherlands; cited November 26, 2011]

Newspaper or Magazine Article

Article author (or news organization if no byline is given). Title of article in sentence case. Newspaper Name Year: Month DD: pp.

Examples:
Roberts JL. Villain or victim? Newsweek 1996; November 4: 40–1.

Schmidt S, Postmedia News. Feds cap caffeine in energy drinks. Warning labels; will have to list nutritional info. The Gazette (Montreal) 2011; October 7: A7.

If the article is available online, the URL can be added as “[Available online at: <http://FullURL>; cited Month DD, YYYY]” at the end of the reference, if desired.

Example:
Blackwell T. Canadians smuggle in cheaper thalidomide. National Post 2009; May 5. [Available online at: http://www.nationalpost.com/Canadians+smuggle+cheaper+Thalidomide/1563133/story.html; cited June 10, 2010]

Special Formats

If a journal article is not a research paper or abstract (that is, it is a letter, an editorial, or similar), or if it was published in a language other than English, note the item type or the source language in brackets at the end of the title:

Examples:
Enzensberger W, Fischer PA. Metronome in Parkinson’s disease [letter]. Lancet 1996;347:1337.

Fujita Y, Yamamoto K, Aomori T, Murakami H, Horiuchi R. Comparison of dissolution profile and plasma concentration–time profile of the thalidomide formulations made by Japanese, Mexican and British companies [Japanese]. Yakugaku Zasshi 2008;128:1449–57.

If a journal article has an associated correction, note the details of the published erratum at the end of the reference:

Example:
Douillard JY, Rosell R, De Lena M, et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol 2006;7:719–27. [Erratum in: Lancet Oncol 2006;7:797]

Journal articles that have been accepted for publication, but that are not yet online or in print can appear in the reference list as “[in press]” after the journal name. Items that have appeared online but not are not yet in print can appear in the reference list as “[Epub ahead of print]” after the journal name.

Examples:
Chua TC, Esquivel J, Pelz JO, Morris DL. Critical analysis of treatment modality and impact on outcome in peritoneal metastases from colorectal cancer: a systematic review. Ann Oncol 2011;:[in press].

Yung RC, Otell S, Illei P, et al. Improvement of cellularity on cell block preparations using the so-called tissue coagulum clot method during endobronchial ultrasound-guided transbronchial fine-needle aspiration. Cancer Cytopathol 2011;:[Epub ahead of print].

Unpublished Material

Material that does not conform to any of the foregoing categories cannot appear in the reference list. Citations of such material must be placed in the text, in parentheses, immediately after the text being supported by the citation. Alternatively, if the unpublished material is being cited in addition to one or more standard published sources, then an alphabetic footnote should be added to the end of the superscript citation numbers, with the unpublished source cited in the footnote.

Examples:
... A separate article examines responses to the second question (Mathews M, Park AD. Cancer care providers’ perceptions of barriers to identifying cancer patients in financial need. In preparation).

... only one third of an ongoing database of 100 patients seen at CancerCare Manitoba each year are eligible to receive FCR (Johnston J, CancerCareManitoba. Personal communication, 2011).

... there is evidence that resistance may differentially affect some metastases and not others—that is, clonal metastasis42,a.

a Zhong WZ. Genomic heterogeneity between primary tumor and its metastases. Presented at the 3rd International Thoracic Oncology Congress Dresden; Dresden, Germany; September 13–15, 2012.

Figures

Format

Figures for reproduction should approximately fit within the typeset area of the journal. The following resolutions are optimal:

  • Black-and-white line drawings, 600–1200 dpi
  • Line drawings with some grey or coloured lines, 600 dpi
  • Illustrations and photographs, 300 dpi

Authors should supply electronic versions of the figure content in EPS, GIF, TIFF, or JPEG format. Other formats, such PDFs, may be used, but are not preferred. Drawings in made in Microsoft Word and Powerpoint are discouraged, because the display of such drawings varies with the settings of each computer used to view the file. There is no guarantee that such figures will reproduce exactly as intended by the author. Save each figure in a separate file without its title or legend, and use simple file-naming conventions (for example, Figure1, Figure2A).

Submission

All figures are to be individually uploaded in Step 4 of the online submission process. Figures are not to be embedded in the article.

Figure Legends

Figures are to be numbered using arabic numerals (1, 2, 3, and so on) in the order in which they are cited in the article text. If a figure has several panels, each panel should be identified using a uppercase alphabetic character (A, B, C, and so on). Each figure should have a title and an explanatory legend that clearly identifies the meaning of any symbols, arrows, numbers, or abbreviations used in the illustration. The legend should permit the figure to be understood without reference to the text. If the figure has been previously published, a credit line should be included and a permission letter supplied by the author.

Title and legend information for each figure should be included with the article text, grouped and placed at the end of the manuscript, after the reference list. All figures will be placed close to their text citations during article layout. Make sure that each figure is cited in the article text.

Colour Figures

All figures will be printed in black and white in the print version of the journal. Any figures that are to be printed in colour should be specified by the author. Costs associated with colour pages will be covered by the author at a price of $750 CAD per page. Before submission, authors should ensure that any colour figure to be printed in black and white can be understood in grayscale; wherever possible, use patterns or symbols for differentiation instead of solid colours.

Tables

Authors are asked to keep each table to a reasonable size; very large tables packed with data simply confuse the reader. Similarly, try to minimize the use of abbreviations, and if abbreviations must be used, use well-known and accepted forms to minimize the need for the reader to constantly refer to the table legend. The same data should not be presented in both a table and a figure.

Tables are to be numbered using uppercase roman numerals (I, II, III, and so on) in the order in which they are cited in the article text. Tables should also have a title (above the table) that summarizes the whole table; it should be no longer than 15 words. Every table column and row should be provided with an explanatory title stub, with units of measure applicable to the row or column clearly indicated.

Tables must be formatted using the table tool in a word processing program to ensure that columns of data remain aligned when the file is sent electronically for review. The table should be formatted with a horizontal line above the column title stubs, between the column title stubs and the table body, and at the end of the table body. Vertical lines, color, and shading are not to be used; parts of the table can be highlighted using symbols or bold text, the meaning of which should be explained in the table legend. Tables must not be embedded as figures or spreadsheet files.

When published studies are presented in a table, the studies must appear in order by year of publication from oldest (top) to most recent (bottom), with studies published in the same year being ordered alphabetically by the family name of the first author.

Footnotes follow the table body and should be indicated using superscripted lowercase letters (a, b,c, and so on).  The table legends come after the footnotes and should be as concise as possible. Tables (together with their footnotes and legends) should be completely intelligible without reference to the text.

All tables (including their associated title, footnotes, and legends) should appear in consecutive numerical order after the references and any figure legends. All tables will be placed close to their text citations during article layout. Make sure that each table is cited in the article text.

Return to Top

Manuscript Submission

Logging in/creating an account
Submitting a Paper
Checking the status of your paper
Need help?

Manuscripts must be submitted online via the Current Oncology online manuscript submission and review system at http://www.current-oncology.com/.

Registration and login are required to submit items online and to check the status of current submissions.

The guidelines below contain information pertaining to online manuscript submission. The following information will help you submit manuscript to the Current Oncology Web-based peer review system. Once you have submitted your article, you will be able to monitor the progress of your manuscript through the peer review process.

Before submitting a manuscript, please gather the following information:

  • For all authors:
    • First and last names
    • E-mail addresses
  • Title (you can copy and paste this from your manuscript)
  • Abstract (you can copy and paste this from your manuscript)
  • Key words
  • Cover letter (optional)
  • Manuscript files in Word
  • Figures/images as separate files in appropriate format as outlined in the manuscript preparation guidelines. Tables must be included in manuscript file, as per the instructions.

Logging in/creating an account

Already have a username/password for Current Oncology?

All authors, reviewers and editors must log in to use the system.

If you are already registered with the system, you may login to the Current Oncology Web site by clicking on Login/Register link at the top of the page and then filling in your username and password. If you do not remember your username or password, click here.

You must ensure you are enrolled as an author to submit a manuscript. To check go to “Edit My Profile” under “My account” on the user home page. Under “roles” ensure the box beside “author” is checked off.

GO TO LOGIN

Need a username and password?

In order to submit an article, you must first register as an author and create a username and password. Once you have created an account with the Current Oncology Web site, you will be able to submit a paper, and track its progress. You can edit your account at any time by logging in and selecting "Edit My Profile" in the User Home.

Be sure to select Author in the “Register As” section of the page, or you will not be able to submit a manuscript.

GO TO REGISTRATION

Submitting a Paper

Submission Steps (5 Step Process)
Decisions
Revisions
Copyediting
Proofreading

Once logged in you may click the link “New Submission” on the User Home Page, OR after clicking “Author” from the User Home page, you may submit an article by selecting “Click Here” under "Start a New Submission". Once selected, the next page will be step 1 of the 5-step online submission process.

Submission Steps (5 Step Process)

Step 1: Starting the Submission
Step 2: Uploading the Submission
Step 3: Entering the Submission's Metadata
Step 4: Uploading Supplementary Files
Step 4a: Add a Supplementary File (Enter Metadata)
Step 5: Confirming the Submission

Step 1: Starting the Submission

Under "Journal Section”, a drop down menu will be available containing a list of submission types (eg. Original Article, Review Article, Case Report etc.). The author will be asked to select the appropriate section for the submission. If the submission is an original article, the author will be asked to indicate the appropriate sub-section (ie: Medical Oncology, Radiation Oncology, etc). The author must then complete the submission checklist indicating the submission is prepared in the proper format as required by the Journal. The "Copyright Notice" must be check off nest thus agreeing that copyright for articles published in Current Oncology is retained by the publisher, Multimed Inc. “Comments for the Editor” section is optional. The author may add any relevant comments here. Select Save/Continue to proceed to the next section.

Step 2: Uploading the Submission

To upload a manuscript to this journal, complete the following steps.

  • On this page, click Browse (or Choose File) which opens a Choose File window for locating the file on the hard drive of your computer.
  • Locate the file you wish to submit and highlight it.
  • Click Open on the Choose File window, which places the name of the file on this page.
  • Click Upload on this page, which uploads the file from the computer to the journal's Web site and renames it following the journal's conventions.
  • Once the submission is uploaded, click Save and Continue at the bottom of this page.

To view the file which was uploaded, click on the file name. If the incorrect file was uploaded, click "Browse" beside the "Replace Submission File" field and follow the above steps.

Step 3: Entering the Submission's Metadata

The first, middle, and last name, and e-mail address of each author must be added. To add additional authors click "Add Author". The "Principal Contact for Editorial Correspondence" must also be selected here. Next, spaces are provided for the "Title and Abstract" of the submission. Keywords may be added in the space provided in the "Indexing" section. Last, a space is available for the author to name any "Supporting Agencies" which provided funding or support for the work presented in the submission.

Step 4: Uploading Supplementary Files

In this step, all figures associated with the manuscript must be uploaded. For articles submitted to the Practice Guidelines section, a completed “author declaration of acceptance/suggested reviewer form” must also be uploaded in this step. In addition, cover letters to the editor, special permission to use figures, copyright release statements, may be included in this step. Note: Tables are not to be uploaded in this step; they are to be included in the manuscript (in Step 2).

  • On this page, click Browse (or Choose File) which opens a Choose File window for locating the file on the hard drive of your computer.
  • Locate the file you wish to submit and highlight it.
  • Click Open on the Choose File window, which places the name of the file on this page.
  • Click Upload on this page, which uploads the file from the computer to the journal's Web site
  • You will then be asked to enter the metadata for the file

Step 4a: Add a Supplementary File (Enter Metadata)

In this step, it is important to only complete the following:

  • Enter “Title” that describes the file. For figures, the title must correspond with the figure names in the manuscript ex: Figure 1, Figure 2, etc.
  • If the file is a figure, ensure that “Present file to reviewers (without metadata), as it will not compromise blind review” is checked off under the heading “supplementary file” near the bottom of the page.

If the incorrect file was uploaded, click "Browse" beside the "Replace File" field.

Click Save and Continue at the bottom of this page to review files uploaded. To upload additional files, use the browse and upload tool and repeat step 4 and 4a.

Once you have uploaded all of the necessary files, click “save and Continue” to proceed to step 5.

Step 5: Confirming the Submission

This step allows the author to review the submission for accuracy, and review the files for submission. The author should click “Finish Submission” to compete the submission process. The submission's principal contact will receive an acknowledgement by e-mail and will be able to view the submission's progress through the editorial process by logging in to the journal Web site.

Decisions

You will be notified by e-mail once a decision regarding you paper has been made. You should receive notification of the initial decision within 2–6 weeks of submission. If any further steps are required, they will be outlined in the e-mail.

Revisions

When a revision of a manuscript is requested, it is essential that you carefully follow the instructions given in the Editor's e-mail, which includes the comments from reviewers (point-by-point). You may also be directed to view any uploaded files from the reviewer, which can be accessed from the review tab (see instructions under “Uploading a Revised Article” on how to access Review page). Please include your response to reviewers on the first page(s) of your revised manuscript file. Failure to do so will cause a delay in the review of your revision and may result in return of the revision to you, without review, for proper preparation.

Uploading a Revised Article

You must log into the Current Oncology Web site and then select "Author" from your profile. Please click on the title of the manuscript that you wish to upload a revision for.

Clicking the title of the manuscript will take you to another page where you will see 3 tabs at the top of the page; Summary, Review, and Editing. Click on the "Review" tab.

Scroll down to the bottom of the page to the "Editor Decision" section. This is where you upload the revised manuscript (which also contains your response to reviewer comments).

To upload the revised manuscript, select "Browse" beside "Editor Decision". Once you locate the manuscript on your computer, select "Upload".

If you have revised figures to upload, see instructions below. If you do not have revised figures, click on the envelope icon beside “Notify Editor” to send an e-mail to the editors letting them know that a revised manuscript has been uploaded.

Uploading Revised Figures

To upload revised figures, please select the "Summary" tab at the top of the page. In the “Submission” section there is a link entitled “Add a Supplementary File”. Here you can upload revised files. You must only enter the “Title” for the file. Please remember to re-name the files ex: Figure 1 - Revised.

Once your revised manuscript and revised figures (if applicable) have been uploaded, click on the letter icon (e-mail notification) to notify the editor that your revised manuscript has been submitted.

Copyediting

After final acceptance of your manuscript, it will be copyedited before publication to conform to Current Oncology style and usage. This editing may be substantive. It is the responsibility of the corresponding author to read the copyedited manuscript he or she will receive and to answer all queries fully.

Proofreading

Prior to the publication of a manuscript, it is required to be proofread by the author at two stages; copyediting and layout. An e-mail message with instructions and a link will be sent to the corresponding author. It is the author’s responsibility to complete the proofreading in a timely manner.

Checking the status of your paper

To check the status of a paper you have already submitted, login to your Current Oncology account go to the User Home and select Author. From there you will see a listing of all the papers you have submitted to Current Oncology. Select the paper you have submitted and you will be able to see detailed information regarding the status of your paper.

Need help?

If you require any technical assistance, please contact:
Amanda Shand (E-mail: amanda_shand@multi-med.com)
Phone: 905-875-2456

Return to Top

 

Submission Preparation Checklist

As part of the submission process, authors are required to check off their submission's compliance with all of the following items, and submissions may be returned to authors that do not adhere to these guidelines.

  1. I have read the Information for Authors and about the peer review process for Current Oncology.
  2. It is understood by the submitting authorship that some manuscripts will be selected to be published in “online-only” format. These decisions are based on the available print pages, and do not reflect the importance of a particular article. All online-only articles are published in full, with a DOI (digital object identifier), and are fully indexed. They will also be listed in the Table of Contents of the hard copy.
  3. Submission files are prepared in the correct format:
    1. Main manuscript format: At least line-an-a-half spacing throughout, including the references and figure legends. The submission file is in Microsoft Word document file format.
    2. Tables: Are formatted using the table tool in a word processing program. All tables (including associated title and legend) appear in consecutive numerical order after the references in the main manuscript file. All tables will be inserted into the correct place during the layout stage.
    3. Figures: Must be submitted as separate files (Step 4 of submission process) in accepted format and not embedded in the manuscript.
  4. By submitting to the journal, the author(s) hereby agree that the submission follows the journals policies on Authorship, Conflict of Interest, Informed Consent, and Human and Animal Rights which are sourced in turn from the International Committee of Medical Journal Editors ("Uniform Requirements for Manuscripts Submitted to Biomedical Journals").
  5. The submission has not been previously published nor is it before another journal for consideration; nor will it be until after such time as the manuscript has either been withdrawn from further consideration or it has been decided that the manuscript will not be published in Current Oncology or an explanation has been provided to the Editor and written permission obtained.
  6. Author Fees: It is understood that an Article Processing Fees (APF) and Extra Page Charge (EPC) is payable for articles accepted for publication in Current Oncology. The APF is $750.00 CAD, which includes up to four black & white published pages. An EPC of $100.00 CAD per black & white page will apply for each additional published page over four pages. Guest editorials, cancer narratives, commentaries and letters to the editor are exempt from paying this fee. For more information on Author Fees, and frequently asked questions, please click here. Please note the following:
    1. Separate publication fees apply to meeting reports, proceedings and meeting abstracts. For a quote or more information contact Laura Hope (E-mail: laura_hope@multi-med.com, Phone: 905-875-2456).
    2. The payment of the Article Processing Fee (APF) or Extra Page Charge (EPC) does not determine in which format your article will be published. It is at the discretion of the editor whether your article is published in full in both print and online, or published in online only format.
    3. Author Fee waivers or discounts are granted on a case-by-case basis to authors who lack funds. To apply for a waiver or discount, please complete and return the author fee waiver form.
    4. Current Oncology offers authors optional Fast Track Publication Author Fee Premiums. Upon acceptance, the article will be published within 2-4 months. Please visit “About Fast Track Publication” for more information.
    5. To help determine the approximate author fees for an article, please send an email to current_oncology@multi-med.com for an estimated published page count. Please provide your full article in word document format, along with any figures and tables. If the manuscript has already been submitted, please provide the manuscript title or ID. Please note an accurate page count of your article and the associated fees can only be determined once the article is in final PDF galley format.
 

Copyright Notice

Copyright for articles published in Current Oncology is retained by Multimed Inc. For permission or reprint requests please click here. Current Oncology authors are required to sign a copyright transfer agreement upon acceptance of their article. Author rights are outlined in the agreement.

 

Author Fees

This journal charges the following author fees.

Standard Article Processing Fee: 750.00 (CAD)

Standard Author Fees

If your manuscript is accepted for publication, you will be asked to pay an Article Processing Fee (APF). The APF is $750.00 CAD, which includes up to four black & white published pages. An Extra Page Charge (EPC) of $100.00 CAD per black & white page will apply for each additional published page over four pages. Authors will be notified of any extra page charges upon receipt of galley proofs. To learn more, please visit our Author Fees section. Upon acceptance, articles will typically be published within 6 months. Publication format is not determined by payment of the Standard Author Fees. It is at the discretion of the Editor whether your article will be published in full in both print & online format, or online only format.

The APF and EPC will apply to all manuscripts including; original articles, review articles, case reports, practice guidelines, short communications, and perspectives in oncology articles. Letters to the editor, cancer narratives, commentaries, editorials and invited guest editorials are exempt from paying this fee.

Separate publication fees apply to meeting reports, proceedings and meeting abstracts. For a quote or more information on publishing with Current Oncology, contact Laura Hope (E-mail: laura_hope@multi-med.com, Telephone: 905-875-2456).

If an author is unable to support the Article Processing Fee of Extra Page Charge, it is his or her responsibility to inform Multimed Inc. by completing and returning our fee waiver form for our consideration, after his or her manuscript has been accepted for publication. The publication of your article is not dependent on the ability to pay the article processing fees or extra page charge. We do not want fees to prevent the publication of worthy work. Please complete and return fee waiver form to Multimed Inc. upon manuscript submission.

Fast Track Publication Fee (Optional)

Current Oncology offers authors Fast Track Publication Author Fee Premiums. Upon acceptance, the article will be published within 2-4 months. The article can be published in print & online or online only format. Fast Track Publication requires timely author response in the review and editing stages.

For fast track publication, contact Laura Hope at laura_hope@multi-med.com prior to submission of the article to the journal or upon manuscript acceptance. The fees for Fast Track Publication are below.

For Non-profit/government/institutions/authors:

  • Print & Online publication = $1,000.00 CAD, per page, standard journal format (black & white)
  • Online Only publication = $750.00 CAD, per page , standard journal format

For Industry:

  • Print & Online publication = $1,500.00 CAD, per page, standard journal format (black &white)
  • Online Only publication = $1,000.00 CAD, per page, standard journal format

About Standard Author Fees

There are Article Processing Fees (APF) and Extra Page Charges (EPC) for articles that are submitted and accepted to Current Oncology.

Upon acceptance, articles will typically be published within 6 months. Publication format is not determined by payment of the Standard Author Fees. It is at the discretion of the Editor whether your article will be published in full in both print & online format, or online only format.

Current Oncology offers authors optional Fast Track Publication Author Fee Premiums. Upon acceptance, the article will be published within 2-4 months. Please visit “About Fast Track Publication” for more information.

NOTE: Separate publication fees apply to meeting reports, proceedings and meeting abstracts. For a quote or more information on publishing with Current Oncology, contact Laura Hope (email : laura_hope@multi-med.com, Phone: 905-875-2456).

Frequently Asked Questions

Why are these APF and EPC being charged?
How much are the APF and EPC?
How can I determine the approximate author fees beforehand?
When will this APF and EPC be charged?
Do I have to pay this APF and EPC? Will authors who do not have funds to pay publication charges be prevented from publishing in Current Oncology?
Will APF and EPC apply to all articles?
Are there any exemptions for APF and EPC?
Who can pay the APF and EPC?
What time period do I have within which to make the payment?
How will you ensure that the payment of publication charges by authors has no influence on whether an article is accepted for publication in a particular journal?

Why are these APF and EPC being charged?
There are substantial costs associated with publishing a high quality, peer-reviewed journal, such as Current Oncology, including:

  • Administration of the editorial and peer-review process
  • Production of the published online and print version (including professional copyediting and preparation into PDF and HTML formats)
  • Gratis print distribution to the Canadian oncology community
  • Development of online functionality and tools
  • Deposit to PubMed, PubMed Central, and CrossRef

Under a subscription-based model, these costs are primarily covered by charging libraries and individuals for access to the journal's content. Under Current Oncology’s Open Access model, we aim to cover the costs of publication primarily through a combination of author charges, and industry sponsorship and advertisements.

How much are the APF and EPC?
The APF is $750.00 CAD, which includes up to four black & white published pages. An extra page charge (EPC) of $100.00 CAD per black & white page will apply for each additional published page over four pages. The payment of the APF or EPC does not determine in which format your article will be published. It is at the discretion of the editor whether your article is published in full in both print and online, or published in online only format.

How can I determine the approximate author fees beforehand?
To help determine the approximate author fees for an article, please send an email to current_oncology@multi-med.com for an estimated published page count. Please provide your full article in word document format, along with any figures and tables. If the manuscript has already been submitted, please provide the manuscript title or ID. Please note an accurate page count of your article and the associated fees can only be determined once the article is in final PDF galley format.

When will this APF and EPC be charged?
The APF and EPC will only apply to articles that are accepted for publication. Upon acceptance, you will be asked to pay the APF through our online store at www.current-oncology.com  (for instructions on how to pay these fees through our peer-review system, click here). This fee of $750.00 CAD must be paid prior to sending your article for copyediting. For exemptions, please click here.

Once your galley proof is available in final PDF format, you will be sent a form advising you of the EPC (for each additional page over 4 pages). You will be asked to complete and return this form with payment by Visa, MasterCard, cheque or money order.

Do I have to pay this APF and EPC? Will authors who do not have funds to pay publication charges be prevented from publishing in Current Oncology?
If an author is unable to support this article processing fee, it is his or her responsibility to inform Multimed Inc. by completing and returning our fee waiver form, for our consideration, after his or her manuscript has been accepted for publication. The publication of your article is not dependent on the ability to pay the article processing fees or extra page charge. We do not want fees to prevent the publication of worthy work.

Will APF and EPC apply to all articles?
The APF and EPC will apply to all manuscripts including; original articles, review articles, case reports, practice guidelines and consensus statements, short communication, and perspectives in oncology articles.

NOTE: Separate publication fees apply to meeting reports, proceedings and meeting abstracts. For a quote or more information on publishing with Current Oncology, contact Laura Hope (e-mail : laura_hope@multi-med.com, Phone: 905-875-2456).

Are there any exemptions for APF and EPC?
Letters to the editor, cancer narratives, commentaries, editorials and invited guest editorials are exempt from paying this fee.

Who can pay the APF and EPC?
The APF and EPC must be paid for by the corresponding author or co-author(s), or their institutions.

What time period do I have within which to make the payment?
Upon acceptance and prior to your article being sent for copyediting, you will be asked to pay the APF of $750.00 CAD through our online peer review system, where you can make payment by credit card. Credit card payments are processed immediately. If payment by credit card is not possible, please contact Multimed Inc. by phone at 905-875-2456, or by e-mail to current_oncology@multi-med.com.

For EPC, the fee is due within 30 days of the extra page charge form date.

How will you ensure that the payment of publication charges by authors has no influence on whether an article is accepted for publication in a particular journal?
Each article goes through the journal's rigorous process of editorial consideration and peer review, thereby ensuring that the high standards of the journal are maintained. The fee is only applicable once the article is accepted for publication. The author charge system will be administered by the publisher, Multimed Inc, once manuscripts have been accepted for publication.

Return to Top

About Fast Track Publication

What is Fast Track Publication?
Current Oncology offers authors optional Fast Track Publication Author Fee Premiums. Upon acceptance, the article will be published within 2-4 months.  The article can be published in print & online or online only format, depending on the fee paid. Fast Track Publication requires timely author response in the review and editing stages.

What are the fees for Fast Track Publication?

For Non-profit/government/institutions/authors:

  • Print & Online publication = $1,000.00 CAD, per page, standard journal format (black & white)
  • Online Only publication = $750.00 CAD, per page , standard journal format

For Industry:

  • Print & Online publication = $1,500.00 CAD, per page, standard journal format (black &white)
  • Online Only publication = $1,000.00 CAD,  per page, standard journal format

What time period do I have within which to make payment?
The Fast Track Publication fee will be invoiced upon publication of the article. Payment is due within 30 days of invoice date.

To help determine the approximate Fast Track Publication fee for an article prior to publication, please send an email to current_oncology@multi-med.com for an estimated published page count. Please provide your full article in word document format, along with any figures and tables. If the manuscript has already been submitted, please provide the manuscript title or ID. Please note an accurate page count of your article and the associated fees can only be determined once the article is in final PDF galley format.

Who do I contact if interested in Fast Track Publication?
For fast track publication, contact Laura Hope at laura_hope@multi-med.com  prior to submission of the article or upon acceptance to the journal.

Copyright Assignment

Authors submitting manuscripts to Current Oncology do so with the understanding that if a manuscript is accepted, the copyright of the article, including the right to reproduce the article in all forms and media, shall be assigned exclusively to Multimed Inc. The corresponding author will be required to sign a Copyright Transfer form on behalf of all authors. This must be completed and returned to Multimed before an accepted article can be published in the journal. Current Oncology allows authors to retain a number of nonexclusive rights to their published article. See the Copyright Transfer form or Author Rights for details.

Return to Top

Author Rights

As an author, you are granted specific rights for a large number of author uses, which are granted and permitted without the need to obtain specific permission from the copyright holder, Multimed Inc. The article must be properly cited (i.e., author name(s), journal name, copyright year, volume number, inclusive pages, and copyright holder). These author rights are granted and apply only to articles for which you are named as the author or co-author. The author rights include:

  • The right to post a copy of the article on the Authors’ own web site after publication of the printed edition of the Journal, provided that a hyperlink is made to the published version available at www.current-oncology.com;
  • The right to reuse figures or tables created by them and contained in the article in other works created by them;
  • The right to make copies of the article for your own personal use, including for your own classroom teaching use;
  • The right to reproduce, and permit any academic institution where you work at the time, to reproduce, the article for the purpose of course teaching;
  • The right to include the article in full or in part in a thesis or dissertation;
  • The right to make copies and distribute copies of the article to research colleagues, for the personal use by such colleagues (but not commercially or mass distribution (e.g. Email list))
  • Patent and trademark rights and rights to any process or procedure described in the article;
  • The right to present the article at a meeting or conference and to distribute copies of such paper or article to the delegates attending the meeting (permission must be obtained for the printing of 25 copies or more);
  • The right to use the article or any part thereof in a printed compilation of works of the author, such as collected writings or lecture notes (subsequent to publication of the article in the Journal and provided that it is not for commercial use);  and
  • The right to reuse portions or excerpts in other works, with full acknowledgment of its original publication in the journal.

Multimed Inc. sends all articles published in Current Oncology immediately upon online publication, without further intervention from the author, to PubMed Central (PMC), the National Library of Medicine’s full text article archive. All articles are also mirrored in all PMC sites, including PubMed Central Canada. Manuscripts deposited to PMC are freely available to the public, via the internet, upon publication in the journal.

Return to Top

Self-archiving Policy

As an author you are granted the right to post a copy of the article on your own Web site after publication of the printed edition of the Journal, provided that a hyperlink is made to the published version available at www.current-oncology.com.

Multimed Inc. sends all articles published in Current Oncology immediately upon online publication, without further intervention from the author, to PubMed Central (PMC), the National Library of Medicine’s full text article archive. All articles are also mirrored in all PMC sites, including PubMed Central Canada. Manuscripts deposited to PMC are freely available to the public, via the Internet, upon publication in the journal.

CIHR Grant Recipients

Current Oncology meets the requirements of the CIHR Policy on Access to Research Outputs. All of our articles are freely accessible at www.current-oncology.com immediately upon publication. We also send all articles published in Current Oncology, without further intervention from the author, to PubMed Central (PMC), the National Library of Medicine’s full text article archive. All articles are also mirrored in all PMC sites, including PubMed Central Canada. Manuscripts deposited to PMC are freely available to the public, via the internet, immediately upon publication in the journal.

Return to Top

Quick Links to Forms

Application for Waiver of Author Fees

Copyright Transfer Agreement

Galley Approval Form

Author Declaration of Acceptance/Suggested Reviewer Form

Return to Top






Copyright © 2014 Multimed Inc.
ISSN: 1198-0052 (Print) ISSN: 1718-7729 (Online)